SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Emmaus Life Sciences, Inc. – ‘10-K’ for 9/30/17 – ‘R51’

On:  Friday, 12/29/17, at 3:46pm ET   ·   For:  9/30/17   ·   Accession #:  1615774-17-7691   ·   File #:  1-35527

Previous ‘10-K’:  ‘10-K’ on 12/22/16 for 9/30/16   ·   Next:  ‘10-K’ on 12/11/18 for 9/30/18   ·   Latest:  ‘10-K’ on 3/31/23 for 12/31/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/29/17  Emmaus Life Sciences, Inc.        10-K        9/30/17   71:8.8M                                   S2 Filings LLC/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    987K 
 2: EX-4.3      Instrument Defining the Rights of Security Holders  HTML     17K 
 3: EX-21.1     Subsidiaries List                                   HTML     18K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     20K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
16: R1          Document and Entity Information                     HTML     49K 
17: R2          Consolidated Balance Sheets                         HTML    106K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
19: R4          Consolidated Statements of Operations               HTML     68K 
20: R5          Consolidated Statements of Changes in               HTML     83K 
                Stockholders' Equity (Deficit)                                   
21: R6          Consolidated Statements of Cash Flows               HTML    112K 
22: R7          Nature of Operations                                HTML     42K 
23: R8          Summary of Significant Accounting Policies          HTML     78K 
24: R9          Convertible Debt and Equity Financings              HTML    151K 
25: R10         Derivative Liabilities                              HTML     52K 
26: R11         Stockholders' Equity                                HTML    239K 
27: R12         Income Taxes                                        HTML     51K 
28: R13         Related Party Transactions                          HTML     63K 
29: R14         Loss Per Share                                      HTML     35K 
30: R15         Commitments and Contingent Liabilities              HTML     39K 
31: R16         Significant Customers                               HTML     23K 
32: R17         Subsequent Events                                   HTML     24K 
33: R18         Summary of Significant Accounting Policies          HTML    138K 
                (Policies)                                                       
34: R19         Summary of Significant Accounting Policies          HTML     25K 
                (Tables)                                                         
35: R20         Convertible Debt and Equity Financings (Tables)     HTML    121K 
36: R21         Derivative Liabilities (Tables)                     HTML     40K 
37: R22         Stockholders' Equity (Tables)                       HTML    184K 
38: R23         Income Taxes (Tables)                               HTML     48K 
39: R24         Related Party Transactions (Tables)                 HTML     40K 
40: R25         Loss Per Share (Tables)                             HTML     34K 
41: R26         Commitments and Contingent Liabilities (Tables)     HTML     29K 
42: R27         Nature of Operations (Details Narrative)            HTML     84K 
43: R28         Summary of Significant Accounting Policies          HTML     26K 
                (Details)                                                        
44: R29         Summary of Significant Accounting Policies          HTML     65K 
                (Details Narrative)                                              
45: R30         Convertible Debt and Equity Financings (Details)    HTML    123K 
46: R31         Convertible Debt and Equity Financings (Details     HTML    185K 
                Narrative)                                                       
47: R32         Derivative Liabilities (Details)                    HTML     56K 
48: R33         Derivative Liabilities (Details Narrative)          HTML     92K 
49: R34         Stockholders' Equity (Details)                      HTML     32K 
50: R35         Stockholders' Equity (Details 1)                    HTML     26K 
51: R36         Stockholders' Equity (Details 2)                    HTML     53K 
52: R37         Stockholders' Equity (Details 3)                    HTML    128K 
53: R38         Stockholders' Equity (Details 4)                    HTML     50K 
54: R39         Stockholders' Equity (Details 5)                    HTML     32K 
55: R40         Stockholders' Equity (Details 6)                    HTML     42K 
56: R41         Stockholders' Equity (Details 7)                    HTML     57K 
57: R42         Stockholders' Equity (Details Narrative)            HTML    611K 
58: R43         Stockholders' Equity (Details Narrative 1)          HTML     48K 
59: R44         Income Taxes (Details)                              HTML     40K 
60: R45         Income Taxes (Details 1)                            HTML     39K 
61: R46         Income Taxes (Details Narrative)                    HTML     25K 
62: R47         Related Party Transactions (Details)                HTML     53K 
63: R48         Related Party Transactions (Details Narrative)      HTML    147K 
64: R49         Loss Per Share (Details)                            HTML     41K 
65: R50         Commitments and Contingent Liabilities (Details)    HTML     42K 
66: R51         Commitments and Contingent Liabilities (Details     HTML     83K 
                Narrative)                                                       
67: R52         Significant Customers (Details Narrative)           HTML     29K 
68: R53         Subsequent Events (Details Narrative)               HTML     36K 
70: XML         IDEA XML File -- Filing Summary                      XML    119K 
69: EXCEL       IDEA Workbook of Financial Reports                  XLSX    105K 
10: EX-101.INS  XBRL Instance -- myan-20170930                       XML   2.60M 
12: EX-101.CAL  XBRL Calculations -- myan-20170930_cal               XML    151K 
13: EX-101.DEF  XBRL Definitions -- myan-20170930_def                XML    843K 
14: EX-101.LAB  XBRL Labels -- myan-20170930_lab                     XML   1.24M 
15: EX-101.PRE  XBRL Presentations -- myan-20170930_pre              XML   1.05M 
11: EX-101.SCH  XBRL Schema -- myan-20170930                         XSD    194K 
71: ZIP         XBRL Zipped Folder -- 0001615774-17-007691-xbrl      Zip    195K 


‘R51’   —   Commitments and Contingent Liabilities (Details Narrative)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.8.0.1
COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)
12 Months Ended
USD ($)
ft²
USD ($)
USD ($)
$ / shares
shares
USD ($)
$ / shares
shares
USD ($)
ft²
USD ($)
ft²
USD ($)
shares
USD ($)
Loss Contingencies [Line Items]                
Accrued Interest             $ 317,000  
Principal Amount             $ 6,000,000 $ 3,000,000
Shares issued on Conversion | shares             1,263,406  
Operating leases monthly lease payments         $ 1,856 $ 4,580    
Operating leases rent expense           84,406 $ 64,900  
Second Omnibus Amendment [Member]                
Loss Contingencies [Line Items]                
Face amount       $ 6,000,000        
Conversion price (in dollars per share) | $ / shares     $ 5.00 $ 5.00        
Accrued Interest     $ 317,000          
Shares issued on Conversion | shares     1,263,406          
Second Omnibus Amendment [Member] | Note Date Range Feb 23, 2016 to August 16, 2016 [Member]                
Loss Contingencies [Line Items]                
Principal Amount             2,000,000  
Second Omnibus Amendment [Member] | Note Date Range Feb 23, 2016 to August 16, 2016 [Member] | Brandt Ventures [Member]                
Loss Contingencies [Line Items]                
Accrued Interest [1]             200  
Principal Amount [1]             $ 50,000  
Shares issued on Conversion | shares [1]             10,047  
Second Amended Note & Warrant Agreement [Member]                
Loss Contingencies [Line Items]                
Face amount       $ 6,000,000        
Conversion price (in dollars per share) | $ / shares       $ 5.00        
Accrued Interest       $ 317,000        
Shares issued on Conversion | shares       1,263,406        
Headquarters and Neurometric Services [Member]                
Loss Contingencies [Line Items]                
Operating leases monthly lease payments           4,809    
Operating leases rent expense           $ 4,809    
Area of land | ft²           2,290    
Commence date           Feb. 01, 2016    
Expiration date           Jan. 31, 2018    
EEG Equipment [Member]                
Loss Contingencies [Line Items]                
Operating leases term of contract   4 months     23 months 15 days      
Operating leases monthly lease payments   $ 9,000     $ 928      
Operating leases rent expense   $ 4,500     $ 1,911      
Area of land | ft²         1,092      
Commence date   Aug. 01, 2017     Feb. 15, 2016      
Expiration date   Aug. 01, 2017     Jan. 31, 2018      
Premises [Member]                
Loss Contingencies [Line Items]                
Operating leases term of contract 3 years              
Operating leases monthly lease payments $ 2,508              
Operating leases next 12 months monthly lease payments 2,576              
Operating leases remaining twelve months monthly lease payments $ 2,647              
Area of land | ft² 1,180              
Commence date Sep. 15, 2017              
Expiration date Sep. 30, 2020              
[1] Brandt Ventures was issued this note as part of the Company's settlement of its litigation with Leonard Brandt and Brandt Ventures (refer to Note 9. Commitments and Contingent Liabilities)

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
9/30/20
1/31/18
Filed on:12/29/17
For Period end:9/30/17
9/15/17
9/14/17
8/1/17
9/30/1610-K
9/21/164,  8-K
9/19/164,  8-K
2/15/16
2/2/16
2/1/16
9/30/1510-K,  8-K,  CORRESP,  NT 10-K,  PRER14A
 List all Filings 
Top
Filing Submission 0001615774-17-007691   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 6, 5:40:07.1pm ET